GENEXGEN INC

Biotech · Private

mRNA-based tolerogenic vaccine using anti-adjuvant technology to suppress immune responses against gene therapy vectors and transgene products

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: GEX: an mRNA-based tolerogenic vaccine for viral-based gene therapies$274,763
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3156SERPLUS TECHNOLOGY, LLC——
3157ASPIREBIO CORPORATION——
3158UNDERDOG PHARMACEUTICALS, INC.——
3159GENEXGEN INC——
3160Basis——
3161SYSTEM BIOSCIENCES, LLC (SBI)——
3162PACDNA LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.